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Cervical cancer is the second most common cancer in Indian women and 4th most 
common cancer in women world-wide. Over nearly two decades, we have carried out 
epidemiological and molecular studies in cervical cancer, with an intent to identify 
potential early diagnostic biomarkers, predictive and prognostic markers, develop 
newer therapies against cervical cancer and identify potential new targets for therapy.
Our studies had identiﬁed 14 high risk and 10 low risk human papilloma virus (HPV) 
in our cervical cancer patients for the ﬁrst time; had identiﬁed life style related co-
factors in the development of cervical cancer (paan chewing, parity, early age at ﬁrst 
sexual intercourse and ﬁrst childbirth, husband with two or more sexual partners). We 
have developed a p16 ELISA kit for cervical cancer screening for use at point of care 
like PHC's; identiﬁed a 7 gene signature which help identify patients who can be 
treated with radiotherapy alone; identiﬁed potential prognostic markers for use in the 
clinic; developed the country's ﬁrst Dendritic cell vaccine therapy for cervical cancer 
and completed the phase 1 study; have identiﬁed newer potential therapeutic targets 
for treatment of cervical cancer.
Keywords: Cervical cancer; Human papilloma virus; p16 ELISA; Predictive and 
Prognostic markers; UBE2C; Dendritic Cell Vaccine for treatment.
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INTRODUCTION :
 Cervical cancer is the 2nd most 
common cancer in Indian women and 4th 
most common world-wide (1). High risk 
human papilloma viruses (HPV) are 
considered to be important in the genesis 
of these cancers (2). However, most of the 
women infected (>95%) will clear the 
infection but a Few can have HPV induced 
pre-cancerous changes which can worsen 
to invasive cancers, indicating that other 
factors are also important in the genesis of 
the cancer. Identifying additional life style 
related factors which increase or decrease 
the risk can help better control the disease 
development.
 Cervical cancer is a disease of 
relatively slow progression, going 
through different grades of dysplasia 
before becoming invasive (3). The 
standard screening procedure for cervical 
cancer is the Pap smear. However, in a 
country as large as India and with a huge 
population load, it is near impossible to 
use PAP smear for screening, simply 
because  we do not  have  enough 
Pathologists/Cytologists. Low cost 
techniques like Visual inspection after 
application of acetic acid (VIA) or Lugol's 
iodine (VILI) have lower sensitivity and 
speciﬁcity. HPV testing has the drawback 
of needing re-testing after a year to 
conﬁrm persistence of infection, as a 
single test cannot conﬁrm if it is a transient 
infection. There is, therefore, an urgent 
need for a simple, low cost and objective 
testing to identify the pre-cancerous 
lesions of the cervix at the Primary Health 
Centres itself.
 The standard line of management of 
stage IIB and stage IIIB till the end of the 
20th century was radical radiotherapy. 
The cure rates with radical radiotherapy 
was around 60% for stage IIB and around 
40% in stage IIIB. The introduction of 
cisplatin based concurrent chemo-
radiotherapy has helped improving the 
cure rates by nearly 10%. The question is, 
can we identify those patients who could 
be cured with the radical radiotherapy 
itself thereby avoiding the cost and 
toxicity of the chemotherapy.
 In view of the stagnation of the cure 
rates newer approaches and newer 
therapeutic agents need to be identiﬁed. 
One promising approach is to use 
therapeutic immune based approaches 
such as Dendritic cell vaccine therapy in 
the treatment of  cervical  cancer. 
Additionally identiﬁcation of newer 
therapeutic targets and development of 
drugs to those targets is essential to 
improve the cure rates in cervical cancer.
A. Epidemiological  s tudies  in 
cervical cancer :
 International Agency for Research 
on Cancer (IARC, Lyon) funded the case 
control study on HPV in cervical cancer 
conducted from June 1998 to May 1999 in 
the Cancer Institute (WIA) (4). Inclusion 
criteria for case subjects were: (i) 
histologic conﬁrmation of invasive 
cervical cancer (ICC) diagnosis; (ii) no 
previous cancer treatment; (iii) lack of 
physical or mental impairments that 
wou ld  have  made  the  in t e rv iew 
impossible; (iv) willingness to provide 
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informed consent. Healthy control women 
were either other patients in the Institute 
or visitors of patients other than women 
with cervical cancer and were age-
matched to ICC cases within 5-year age 
groups. Exclusion criteria for control 
women included: (i) a diagnosis of ano-
genital tract cancers (i.e., cervix, vagina, 
vulva, anal canal), cancer of the breast, 
endometrium, ovary or colon, benign 
genital tumours and tobacco-related 
diseases (e.g., coronary heart disease, 
chronic bronchitis and cancer of the head 
and neck, lung and bladder); (ii) a history 
of hysterectomy or cervical conization; 
(iii) physical or mental problems and (iv) 
not willing to provide informed consent.
 All the cases (n=205) and control 
( n = 2 1 3 )  w o m e n  u n d e r w e n t  a 
g y n a e c o l o g i c  e x a m i n a t i o n  a n d 
ectocervical  & endocervical  cel l 
collection was done using appropriate 
spatulas and brushes. The cells were 
o
stored at -70 C and then shipped to IARC, 
Lyon. HPV detection was done using PCR 
followed by an Enzyme immunoassay 
containing probes which would detect 
high risk and low risk HPV subtypes.
 Af te r  exc lud ing  inadequa te 
samples, we had 191 ICC and 184 control 
women's samples with HPV data. High 
risk HPV was detected in 190/191 cases 
(178/179 squamous cell carcinoma; 12/12 
adenocarcinoma) and in 40 of the 184 
control women. Low risk HPV only was 
seen in 11 of the control women but not in 
ICC cases. HPV infection with any 
subtype was associated 498-fold 
increased ICC risk. HPV16 was the most 
common subtype seen in cases and 
controls, followed by HPV18 and 33. 
Multiple subtype infection was seen in 
17% of cases and 4% of controls. 
 This was the ﬁrst study from the 
country to look at all the HR and LR HPV 
subtypes. It  conﬁrmed the strong 
association of HR-HPV subtypes with 
ICC. It also for the ﬁrst time showed the 
incidence of HR-HPV infection in control 
women to be as high as 22%. The study 
also identiﬁed several risk factors 
including paan chewing with and without 
tobacco (OR 2.3) with a dose dependent 
effect; parity; women with husbands who 
had extramarital affairs; age at ﬁrst 
intercourse <15 years compared to ≥21 
years was associated with OR 2.2;age at 
ﬁrst child birth (<17 years compared to 
≥19 years was associated with OR 2.2); 
more than one sexual partner; all of which 
increased the risk. High vegetable and 
fruits intake was associated with a 
decreased risk for ICC (OR 0.5) (5). The 
data from the study was included in an 
I n t e r n a t i o n a l  C o l l a b o r a t i o n  o f 
Epidemiological studies of cervical 
cancer co-ordinated by IARC, Lyon. This 
r eana lys i s  o f  da ta  invo lv ing  25 
epidemiological studies with more than 
16000 ICC and more than 30,000 controls 
showed:
1. Reproductive factors (6) :
a. The risk for developing invasive 
cervical cancer increases with parity 
(≥7 full term pregnancy compared 
with 1 – 2). 
b. Early age at ﬁrst full term pregnancy 
(<17 years versus ≥25 years) was 
associated with increased risk for 
invasive cervical cancer and for 
CIN3/CIS lesions.
2. Tobacco smoking (7) :
a. Tobacco smoking (current smokers 
and past smokers) had an increased 
risk for squamous cell carcinoma 
(SCC) of cervix. The RR in current 
smokers was 1.6 (95% CI: 1.48 – 
1.73; p<0.001) and in past smokers 
was 1.12 (95%CI: 1.01 – 1.25). 
b. The risk in current smokers for the 
development of SCC of the cervix, 
increased with increasing number 
of cigarettes smoked and on the 
younger age at which they started 
smoking (p<0.001).
c. To b a c c o  s m o k i n g  w a s  n o t 
associated with an increased risk for 
Adenocarcinoma of the cervix.
3. Hormonal contraceptives (8) :
a. Individuals using combined oral 
contraceptives for 5 or more years 
had a RR of 1.9 (95% CI: 1.69 – 
2.13) for the development of 
invasive cervical cancer. 
b. A similar risk was also seen for 
CIN3/CIS.
c. In jec tab le  proges tagen-only 
contraceptives showed a slightly 
raised risk for invasive cervical 
cancer, when used for 5 or more 
years (RR 1.22 [95% CI: 1.01 – 
1.46] p=0.03).
d. The risk of cervical cancer declines 
once the drugs are stopped and by 10 
years or more, the risk is similar to 
that of a never user.
4. Sexual behaviour (9) :
a. A lady with many sexual partners 
(≥6) has more than two fold risk for 
development of invasive cervical 
cancer and for CIN3/CIS, after 
conditioning on age, study and age 
at ﬁrst intercourse.
b. The age at ﬁrst intercourse is also a 
risk determinant, with ≤14 years of 
age at ﬁrst intercourse having a 
greater than 2 fold risk, when 
c o m p a r e d  w i t h  a g e  a t  ﬁ r s t 
intercourse of ≥ 25, and after 
conditioning for age, study, number 
of sexual partners and reproductive 
factors.
5. Education (10) :
a. Low education level was found to 
be associated with cervical cancer 
but not with HPV infection.
B. Molecular studies in cervical 
cancer :
 Microarray studies were carried out 
on normal cervical tissues (n = 5), 
different grades of dysplasia (CIN1 & 2 – 
n = 4; CIN3/CIS n = 4) and ICC (n = 28). 
Differentially expressed genes were then 
validated using quantitative Real Time 
PCR (qRT-PCR). Some of the genes were 
then validated at the protein level using 
Immunohistochemistry (IHC) (11).
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1. p16 ELISA  :
 Our qRT-PCR data identiﬁed p16 as 
being highly expressed in high grade 
CIN3/CIS and in ICC compared to normal 
and low grade CIN1/CIN2. IHC showed 
the protein to be overexpressed in tumours 
and in high grade CINs. We then 
proceeded to develop a sandwich ELISA 
for detection of p16 using commercially 
available antibodies. Concurrently we 
started raising monoclonal antibodies to 
p16 using recombinant p16 protein which 
we had expressed and puriﬁed from 
bacterial cells.
 The  Sandwich ELISA us ing 
commercial antibodies was validated 
using recombinant p16. Once we had the 
monoclonal antibodies raised and 
cha rac t e r i z ed  by  u s ,  we  u sed  a 
combination of the monoclonal antibodies 
in the sandwich ELISA and were able to 
detect reliably 1pg. We then evaluated the 
ELISA using HeLa cells, and were able to 
detect upto 500 cells reliably. One of the 
problem we faced was assessing the 
adequacy of the cervical scrape sample. In 
PAP smear, the Pathologists can assess 
whether the sample is adequate or not for 
interpreting and can order for a fresh 
sample if found inadequate. In an ELISA, 
this was not possible and hence we 
developed and added another ELISA for 
cytokerat in  level .  Cytokerat in  is 
expressed in almost all epithelial cells and 
an antibody against pan-cytokeratin can 
identify the epithelial content. By running 
the p16 and cytokeratin ELISA in parallel, 
we were able to show the adequacy of the 
sample and also determine the levels of 
p16 expression. This was a major advance 
over an existing ELISA kit for p16 
developed and marketed in Germany. We 
have done the preliminary assessment of 
the functioning of the ELISA using well 
annotated clinical samples from Nargis 
Dutt Memorial Cancer Hospital, Barshi, 
wherein a cervical cancer screening 
program has been going on for more than a 
decade. Patent has been applied for the 
p 1 6  k i t  [ A p p l i c a t i o n  n u m b e r 
475/CHE/2014, ﬁled on 03-02-2014]. 
Further validation is being planned by 
using blinded samples from Barshi which 
wil l  be fol lowed by independent 
validation in 3 major centres in India 
involving at least 1000 samples. We are in 
the process of transferring the Technology 
to a Govt. of India subsidiary for 
commercialization of the kit.
2. Predictive markers for radiation 
response in cervical cancer :
 As mentioned earlier, the addition 
of concurrent chemotherapy with radical 
radiation improves the cure rate by around 
10%. However, we do not have a means of 
identifying who would fail treatment, so 
that chemotherapy could be reserved for 
them thereby minimizing toxicity and cost 
of the chemotherapy. To this end we had 
carried out gene expression studies using 
microarray as described in (12) which was 
then validated using qRT-PCR. 
 Using 24 samples from patients who 
had undergone therapy with more than 3 
years follow-up, we developed a scoring 
method based on the qRT-PCR data. The 
cut-off was set at 40% of the potential total 
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score possible. A 7 gene signature score 
was found to identify patients likely to fail 
treatment. At the cut-off score set, all the 
failed samples were identiﬁed as high risk. 
The sensitivity, speciﬁcity, PPV and NPV 
were 0.64, 1.0, 1.0, 0.67, respectively.
 This needs further validation using a 
larger sample size, in samples collected 
from patients who had undergone radical 
radiotherapy only. We are hoping to 
collaborate with other centres which 
would have frozen tumour samples 
available of patients treated with 
radiotherapy only.
3. Prognostic markers for cervical 
cancer :
 At the Institute, most of the cervical 
cancer cases are stage IIB and IIIB (nearly 
80%) and of high grade (80%). Since stage 
and grade of the tumours are strong 
prognostic indicators, this meant that most 
of our patients were high risk group and 
additional markers are required to better 
sub-stratify them.
 Our department had evaluated 
several proteins for their potential as 
prognostic markers, overexpression of 
BCL2 was found to be associated with 
poor response to treatment with Radical 
radiotherapy and more patients failed 
treatment after achieving a complete 
response, as well (Table 1 – BCL2).  This 
was independent of the stage of disease 
(13). C-myc oncoprotein overexpression 
was also likewise associated with poor 
prognosis independent of the stage (14).
4. Identiﬁcation of molecular targets 
in cervical cancer :
 Based on our gene expression 
studies (microarray and qRT-PCR) we 
identiﬁed several potential targets for 
treatment in cervical cancer, including 
UBE2C, MELK, ISG15, STAT1, MMP3, 
MMP1 (11). 
 UBE2C which is a Ubiquitin 
conjugating enzyme E2C, is expressed at 
high levels in cervical tumours and high 
grade dysplasia but at low levels or is 
absent in normal tissues and low grade 
dysp l a s i a .  Us ing  a  func t iona l ly 
inactivated dominant-negative mutant of 
UBE2C (C114S), we showed that the 
mutant protein alters the tumorigenicity 
(soft agar cloning assay) and sensitises 
cancer cells (cervical cancer cell lines) to 
radiation (Clonogenic assay) (15).
 We are now involved in in-silico 
modelling and docking of compounds to 
t h e  a c t i v e  s i t e  i n c l u d i n g  C 11 4 . 
Compounds showing UBE2C blocking 
activity will be taken forward for further 
evaluation.
C. Development of dendritic cell 
vaccine therapy for cervical cancer :
 Immune perturbation is one of the 
critical factor in the development of 
cancer. Every day in a normal individual 
there are millions of cells undergoing 
proliferation which is essential to 
maintain normal physiological functions. 
Some of the cells undergoing proliferation 
will have error in DNA sequence. The ﬁrst 
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line of defence in this is the DNA repair 
mechanism which can correct the errors 
and if the cell fails to correct the error and 
tries to enter another cell division, 
apoptosis is triggered, so that the 
abnormal cell does not result in clonal 
proliferation. In addition, several 
environmental and dietary factors can 
damage the cellular DNA and again the 
DNA repair mechanisms ensure the DNA 
integrity is maintained. However, in spite 
of well- regulated DNA repair process, 
sometimes the error can be propagated to 
daughter cells. At this level, the immune 
system comes into  play with  i t s 
continuous surveillance, detecting these 
abnormal cells and destroying them. In 
some situations, the immune system is 
also compromised and the developing 
tumour cells can alter its MHC protein 
expression and secrete factors which can 
result in tolerance to the developing 
tumour. There are several ways to break 
the immune tolerance, one of which is to 
use primed dendritic cells to overcome the 
resistance.
 Dendritic cells (DC) are the most 
potent antigen presenting cells and can 
help initiate a strong immune response. In 
the tumour microenvironment, the 
dendritic cells are either inactive or can be 
inhibitory to the immune response due to 
tumour / stroma derived factors such as 
IDO (Indoleamine deoxygenase). We and 
others have shown that DCs can be 
generated from peripheral blood derived 
monocytes and these can then be matured 
into primed dendritic cells and then 
injected back into the patients to generate 
a robust immune response.
1. Generation and characterization 
of mature primed Dendritic cells for DC 
vaccine :
 Under funding from Dept. of 
Biotechnology, Government of India, we 
ﬁrst standardized the protocol for 
generation of DC's and then functionally 
characterized them (16). Brieﬂy, we 
obtained peripheral blood mononuclear 
cells from patients and then plated them in 
plastic petridishes. Monocytes adhere to 
the plate while other cells ﬂoat up and are 
removed and used for functional assays. 
The monocytes are then grown in the 
presence of IL4 and GM-CSF (100ng/ml 
each) in therapeutic grade serum free 
AIM-V medium for 7 days. The ﬂoating 
immature DCs were transferred on the 7th 
day to fresh plate containing AIM-V 
medium and then exposed to tumour 
antigens derived either from patient's own 
tumour lysate or mRNA from the tumour 
for 4 hours. IL-1β and TNF-α are added at 
100ng/ml and incubated for another 3 
days. The mature primed cells were then 
characterized using FACS and functional 
assays.
 Mature primed DC's were HLA-DP, 
DQ, DR +++; CD86++; CD14 negative. 
In contrast, immature DC's were HLA-
DP, DQ, DR +++; CD86+; CD14 
negative, indicating that they are less 
likely to be good antigen presenter due to 
lower levels of co-stimulatory molecule 
CD86. The tumour lysate primed DC's 
were more effective in functional assays 
compared to mRNA primed DC's 
particularly when primed in a ratio of 3 
tumour cell : 1 DC.
2. A Phase 1 clinical trial to evaluate 
the toxicity of DC vaccine in recurrent 
and/or metastatic HPV positive cervical 
cancers  :
 This was a part of the DBT funded 
study. The study was a 3 arm study 
recruiting cervical cancer patients who 
had relapsed or had progressive disease 
after initial radical radiotherapy. Arm 1 
patients received saline; Arm 2 received 
mature unprimed DC's; Arm 3 patients 
received mature tumour lysate (patient's 
own tumour) primed DC's. The inclusion 
and exclusion criteria have been published 
(16). Arm 1 was dropped after recruitment 
of 9 patients, as the DBT review 
committee found a satisfactory difference 
between patients receiving the DC's 
(primed or unprimed) compared to those 
receiving saline. 5 additional patients 
were recruited (3 in Arm 2 and 2 in Arm 3). 
Patients were given 3 doses every 14 days, 
of the appropriate DC vaccine at a 
6
maximum dose of 1 x 10  mature DCs per 
injection.
 The DC vaccine was well tolerated 
with most of the patients having no side 
effects. Itching at the site of injection (1 
patient), grade 1 fever possibly due to 
urinary tract infection (2 patients) and one 
patient had elevated serum Alkaline 
phospha ta se .  The  De layed  Type 
Hypersensitivity (DTH) response was 
evaluated in 11 of the 14 patients 
recruited, with 2/4 Arm 2 and 2/4 Arm 3 
patients tested being positive. In one of the 
Arm 3 patient who had locally persistent 
residual disease and a solitary lung 
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Fig. 1: Progress in the metastatic lung lesion in one of the patient.
Fig. 1a. Lung metastatic lesion detected at patient enrolment (indicated by 
black arrow).  Fig. 1b and c show progression of lesion after vaccination 
(1c. Was taken a year after vaccination). Fig. 1d. Shows complete regression of 
lesion three years after vaccination and 1.5 years after cisplatin chemotherapy. 
The patient is disease free 9 years after the chemotherapy in 2006.
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metastasis after radical radiotherapy, her 
local disease resolved within 6 months 
after her last dose. Her lung lesion 
progressed  and she  was  advised 
symptomatic treatment only at her last 
follow-up in 2005 at which time the lesion 
was pushing her chest wall. In December 
2007, when we were updating our follow-
up information telephonically, she was 
found to be alive and well. She was then 
reviewed at the Institute and was found to 
be free of disease locally and at the 
metastatic site (Fig.1). She continues to be 
free of disease 9 years since receiving 
cisplatin. While cisplatin is known to 
produce complete response in metastatic 
sites, the disease relapses within 18 
months to 2 years. That this patient is free 
of disease for more than 9 years suggests 
tha t  the  DC vacc ine  could  have 
contributed to the sustained disease free 
status by triggering the memory T-cells 
when the tumour antigens were released 
due to the chemotherapy administered. 
The same patient had the strongest 
proliferative response as well as a strong 
DTH response, indicating that her 
immune system had been stimulated well.
 Based on our data, we have been 
now funded by the Department of Science 
and Technology, Government of India for 
conducting a Phase 2 study. This will be a 
3 arm study in untreated stage IIIB 
cervical cancer patients, with Arm 1 
patients receiving standard therapy of 
concurrent chemo-radiation; Arm 2 
patients receiving standard therapy of 
concurrent chemo-radiation plus DC 
vaccine primed with patient's own tumour 
lysate; Arm 3 patients receiving standard 
therapy of concurrent chemo-radiation 
plus DC vaccine primed with SPAG9 
recombinant protein (developed by Prof. 
An i l  Sur i ,  Na t iona l  Ins t i tu t e  o f 
Immunology). DCGI clearance was 
obtained in Feb 2015 and hope to start the 
study by August 2015.
Conclusion : 
 Work summarises our research in 
cervical cancer covering almost all 
aspects of the disease. There are several 
ﬁrsts in the country highlighted here – the 
ﬁrst Epidemiological study to identify 14 
HR HPV and 10 LR HPV subtypes in 
cervical cancer patients and healthy 
controls; ﬁrst to identify a predictive 
marker for identifying patients who can be 
treated with radical radiotherapy alone; 
ﬁrst to develop and conduct a phase 1 
Dendritic cell vaccine clinical trial; ﬁrst to 
develop a low cost ELISA for cervical 
cancer screening. Ours is an on-going 
endeavour to help control the disease.
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